Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Sep 1;11(9):1064-1071.
doi: 10.1001/jamaoncol.2025.1891.

First-Line Therapy For Advanced Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Fausto Petrelli  1 , Elena Verri  2 , Antonio Ghidini  3 , Ivano Vavassori  4 , Veronica Lonati  1 , Franco Nolè  2 , Lorenzo Dottorini  1
Affiliations
Meta-Analysis

First-Line Therapy For Advanced Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Fausto Petrelli et al. JAMA Oncol. .

Erratum in

  • Erroneous References.
    [No authors listed] [No authors listed] JAMA Oncol. 2025 Sep 1;11(9):1099. doi: 10.1001/jamaoncol.2025.3587. JAMA Oncol. 2025. PMID: 40788655 Free PMC article. No abstract available.

Abstract

Importance: Non-clear cell renal cell carcinomas (nccRCCs) present considerable challenges owing to their heterogeneity and limited clinical trial representation. Understanding the benefits of combining immunotherapy and targeted therapy for these subtypes is crucial for improving patient outcomes.

Objective: To evaluate the efficacy of various first-line immunotherapy combinations and targeted therapy in treating metastatic nccRCC.

Data sources: A systematic literature search was conducted across PubMed, Embase, and Cochrane Library databases from inception until December 31, 2024, using relevant keywords and medical subject headings terms.

Study selection: Studies were included if they involved patients with nccRCC, reported on immune checkpoint inhibitor (ICI)-based therapies, and provided data on objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and disease control rate (DCR).

Data extraction and synthesis: Two independent reviewers extracted data, with discrepancies resolved by a third expert. Observational study quality was assessed using the Newcastle-Ottawa Scale. A random-effects meta-analysis was performed, and heterogeneity was evaluated using the I2 statistic.

Main outcome and measures: The primary outcomes of interest were ORR, PFS, OS, and DCR.

Results: The analysis included 23 studies encompassing various subtypes of nccRCC. Pooled results indicated an ORR of 26.6% and a DCR of 57.8% for nccRCC treatments. Median PFS was 6.59 months, and the median OS was 21.11 months. ICIs demonstrated significant efficacy in nccRCC, exhibiting marked clinical activity across different subtypes. Although monotherapy with ICIs showed effectiveness, combination therapies yielded superior clinical outcomes.

Conclusions and relevance: This systematic review and meta-analysis found that ICIs, particularly when combined with targeted therapies, showed promising efficacy in treating metastatic nccRCC. These findings support their integration into treatment guidelines and emphasize the importance of personalized treatment strategies. Future research should focus on long-term outcomes, safety profiles, and the identification of biomarkers to optimize patient selection and improve outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

References

    1. Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. doi: 10.1038/nrdp.2017.9 - DOI - PMC - PubMed
    1. Zarrabi K, Walzer E, Zibelman M. Immune checkpoint inhibition in advanced non-clear cell renal cell carcinoma: leveraging success from clear cell histology into new opportunities. Cancers (Basel). 2021;13(15):3652. doi: 10.3390/cancers13153652 - DOI - PMC - PubMed
    1. Bellmunt J, Dutcher J. Targeted therapies and the treatment of non-clear cell renal cell carcinoma. Ann Oncol. 2013;24(7):1730-1740. doi: 10.1093/annonc/mdt152 - DOI - PubMed
    1. Linehan WM, Spellman PT, Ricketts CJ, et al. ; Cancer Genome Atlas Research Network . Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374(2):135-145. doi: 10.1056/NEJMoa1505917 - DOI - PMC - PubMed
    1. Haddad AQ, Margulis V. Tumour and patient factors in renal cell carcinoma-towards personalized therapy. Nat Rev Urol. 2015;12(5):253-262. doi: 10.1038/nrurol.2015.71 - DOI - PubMed

MeSH terms

Substances